Recent Posts
- Salubris Biotherapeutics Presents Updated Expansion Cohort Data for JK06, 5T4-Targeted Antibody Drug Conjugate, at the American Society for Clinical Oncology
- Salubris Biotherapeutics Announces Expansion Cohort Data for JK06, 5T4-Targeted Antibody Drug Conjugate, at the American Association for Cancer Research Conference
- Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress
- ESMO 2025 Poster Presentation: A Phase 1/2 Study of JK06, a 5T4-Targeted Antibody Drug Conjugate (ADC), in Patients with Unresectable Locally Advanced or Metastatic Cancer
- Salubris Biotherapeutics Provides Updates on JK07 and JK06 Clinical Programs
Recent Comments